west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "拉米夫定" 20 results
  • 拉米夫定致听力障碍的不良反应一例

    【摘要】 目的 报道1例拉米夫定引起听力障碍的不良反应。 方法 对不良反应发生的过程及原因进行阐述及分析。 结果 患者听力障碍的不良反应系由拉米夫定引起的。 结论 拉米夫定可引起听力障碍的不良反应,临床应用中应引起重视。

    Release date:2016-09-08 09:27 Export PDF Favorites Scan
  • Antivirus Therapy of Lamivudine Resistant Chronic Hepatitis B Patients

    目的 采用干扰素和阿德福韦酯治疗慢性乙型肝炎患者经拉米夫定治疗后出现YMDD变异,比较两种治疗策略的临床疗效。 方法 选择2002年2月-年12月经100 mg拉米夫定治疗后出现YMDD变异的慢性乙型肝炎患者76例。其中,男52例,女24例;年龄18~55岁,平均年龄33岁。服用100 mg拉米夫定52~156周发生YMDD变异,HBV DNA低于治疗前水平,丙氨酸转移酶(alanine aminotransferase,ALT)lt;2×ULN/L患者分为A组(26例),继续用100 mg拉米夫定治疗48周;服用100 mg拉米夫定52~156周发生YMDD变异,HBV DNA定量检测高于或等于治疗前水平,ALTgt;2×ULN/L,根据患者自愿分为B组(27例)和C组(23例)。B组用100 mg拉米夫定联合10 mg阿德福韦酯治疗48周;C组用干扰素治疗48周。分别观察3组ALT复常率及HBV DNA转阴率、HBeAg阳性患者血清学转换率。 结果 治疗48周时,B、C组患者ALT复常率分别是74.1%和78.3%,明显高于A组的34.6%,差异有统计学意义(Plt;0.05);B、C组患者HBV DNA转阴率分别是77.7%和73.9%,明显高于A组的11.5%,差异有统计学意义(Plt;0.05);3组HBeAg阳性患者血清学转换率比较,差异均无统计学意义(Pgt;0.05)。 结论 慢性乙型肝炎患者经拉米夫定治疗后出现YMDD变异,继续用拉米夫定治疗疗效不理想,改用干扰素或联合阿德福韦酯治疗更安全有效。

    Release date:2016-09-08 09:47 Export PDF Favorites Scan
  • Efficacy of Antiviral Drugs for Hepatitis B with YMDD Motif Variant: A Systematic Review

    Objective To evaluate the efficacy and safety of antiviral drugs for hepatitis B with YMDD motif variant. Methods We electronically searched MEDLINE (1989-April, 2004), EMBASE (1989-April, 2004), CBMdisc (expand) (1989-April, 2004), and handsearched unpublished Chinese conference proceedings. Randomized and quasi-randomized trials in patients with chronic hepatitis B with YMDD motif variant correlative to lamivudine were collected. Two reviewers extracted the data and assessed the quality of literature independently. The data were then analyzed by RevMan 4.2 software. Results Five studies involving 6 trials and 284 patients were included. According to the results of meta-analysis, antiviral therapy with adefovir plus lamivudine showed significantly better effects on the clearance of serum HBV-DNA and HBeAg and normalization of ALT than that of lamivudine alone (RR 16.61, 95%CI 2.29 to 120.71; RR 6.66, 95%CI 1.23 to 35.88 and RR 6.26, 95%CI 2.29 to 17.12 respectively); also, oxymatrine plus thymothin showed obviously better effects on the clearance of serum HBV-DNA and HBeAg (RR 2.96, 95%CI 1.26 to 6.93 and RR 2.51, 95%CI 1.05 to 5.98 respectively).But adefovir alone showed no better effects on clearance of serum HBV-DNA and HBeAg than that of lamivudine alone (RR 11.00, 95%CI 0.65 to 186.02 and RR 7.00, 95%CI 0.39 to 126.92 respectively); interferon plus lamivudine showed no better effects on the clearance of serum HBV-DNA, HBeAg and the normalization of ALT (RR 3.50, 95%CI 0.90 to 13.58; RR 4.90, 95%CI 0.70 to 35.10 and RR 2.80, 95%CI 0.91 to 8.12 respectively). Chinese herbs plus lamivudine showed no better effects on the clearance of serum HBV-DNA (RR 1.16, 95%CI 0.89 to 1.51). There were no significant side effects in the groups, except flu like symptom in the interferon group, slight kidney impairment in the adefovir group, and aggravation of rare cases in lamivudine group. Conclusions Antiviral therapy with adefovir plus lamivudine, or oxymatrine plus thymothin, shows better effects than with lamivudine alone in terms of antiviral therapy and clinical outcome improvement. However, the evidence is too weak to draw a definite conclusion in this systematic review. Larger sample size and rigorously designed randomized, double blind, placebo control trials are required for future study.

    Release date:2016-09-07 02:27 Export PDF Favorites Scan
  • Prophylactic Effect of Lamivudine Monotherapy Against Hepatitis B Recurrence Following Liver Transplantation

    【Abstract】ObjectiveTo investigate the prophylactic effect of lamivudine monotherapy on the recurrence of hepatitis B after liver transplantation. MethodsThirtyone patients with hepatitis B related benign decompensated cirrhosis who underwent liver transplantation between February 1999 to June 2002 and survived more than 3 months were analyzed retrospectively. Lamivudine was administered to each patient after operation and some patients before operation for the prophylaxis of HBV recurrence. The HBV markers and HBV DNA in serum and bioptic liver tissues in all patients were evaluated before and after operation. ResultsTotal HBV recurrence rate was 19.4%(6/31) during average 38.2 months (3.2-70.2 months) follow up. HBV recurrence rate was 7.1%(2/28), 16.0%(4/25), 26.1%(6/23) and survival rate was 87.1%(27/31), 80.6%(25/31), 66.1%(20.5/31) after 1-, 3-and 5-year, respectively. One hundred milligram lamivudine administration peroral daily for 2 weeks prior to transplantation enable HBeAg 54.5%(6/11) and HBV DNA 50.0%(5/10) positive patients convert to negative respectively. ConclusionPreoperative administration of lamivudine monotherapy can effectively prevent allograft from HBV re-infection after liver transplantation. Lamivudine should be used to convert HBV DNA and HBeAg to negative.

    Release date:2016-09-08 11:52 Export PDF Favorites Scan
  • 拉米夫定在慢性乙型肝炎抗病毒治疗中的进展

    【摘要】 文献总结了10余年拉米夫定在慢性乙型肝炎抗病毒治疗的效果分析,包括临床疗效、经济-成本、生存质量等相关指标的分析以及耐药管理等问题。

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
  • Combination Therapy with Lamivudine and HBIG versus Lamivudine Monotherapy in Prevention of Hepatitis B Virus Recurrence after Liver Transplantation: A Systematic Review

    Objective To evaluate the effectiveness of combination therapy with lamivudine (LAM) and hepatitis B immunoglobulin (HBIG) versus LAM monotherapy in prevention of hepatitis B virus recurrence after liver transplantation. Methods Databases including MEDLINE (Ovid), PubMed, EMbase, Cochrane Central Register of Controlled Trials (CENTRAL), CBM, VIP, and CNKI were searched up to Dec. 2008. Clinical trials including randomized controlled, non-randomized concurrent-control and case-control studies about combination therapy with HBIG and LAM versus LAM monotherapy in prevention of hepatitis B virus recurrence after liver transplantation were screened. Trial selection and data extraction were conducted by two reviewers independently. Meta-analysis was performed using RevMan 5.0.18 software. Results Eleven non-randomized concurrent-control studies involving 1 421 patients (1 035 patients in combination therapy group, and 386 patients in LAM monotherapy group) were included. The results of meta-analyses showed: Compared with LAM monotherapy group, the risks of hepatitis B virus recurrence, YMDD mutation, and death associated with HBV recurrence were significantly reduced by 73% (RR=0.27, 95%CI 0.20 to 0.37, Plt;0.000 01), 72% (RR=0.28, 95%CI 0.15 to 0.53, P=0.000 01), and 79% (RR=0.21, 95%CI 0.09 to 0.49, P=0.000 3) respectively in combination therapy group after liver transplantation; overall survival rates of both recipients and grafts in combination therapy group were similar to LAM monotherapy group (RR=1.03, 95%CI 0.95 to 1.11, P=0.51; RR=1.04, 95%CI 0.97 to 1.12, P=0.26). Conclusion Current evidence indicates that compared with LAM monotherapy, combination therapy with LAM and HBIG could reduce the risks of hepatitis B virus recurrence, YMDD mutation, and death associated with HBV recurrence after liver transplantation.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • Effective Treatment for Patients with Viral Relapse after Adefovir Withdrawl by the Combination of Lamivudine plus Adefovir

    目的 比较拉米夫定+阿德福韦酯联合治疗与阿德福韦酯单药治疗对阿德福韦酯停药后出现病毒学反弹而无基因型耐药变异患者的疗效及安全性。 方法 回顾研究2007年1月-2012年1月在传染科门诊就诊的67例阿德福韦酯治疗获得病毒学应答但停药后出现病毒学反弹的e抗原阳性慢性乙型肝炎患者,分别给予拉米夫定+阿德福韦酯联合治疗(联合组,n=35)和阿德福韦酯单药治疗(单药组,n=32)。 结果 治疗1年后,联合组(32例,85.7%)较单药组(21例,65.6%)有更多的患者重新获得了丙氨酸转氨酶复常(P=0.009),联合组34例(97.1%)乙型肝炎病毒DNA阴转,单药组22例(68.8%)阴转,两组差异有统计学意义(P=0.002);在血清学转换方面,联合组和单药组分别有4例(11.4%)和1例(3.1%)患者获得了e抗原的血清学转换。在治疗中所有患者均未发生任何严重不良反应。 结论 阿德福韦酯停药后出现病毒学反弹,选择拉米夫定与阿德福韦酯联合治疗可使患者重新获得较好的生化学和病毒学应答。

    Release date:2016-09-08 09:17 Export PDF Favorites Scan
  • Lamivudine for HBeAg Positive Chronic Hepatitis B: A Meta-analysis of Randomized Controlled Trials

    Objective To assess the efficacy of lamivudine in patients with HBeAg positive chronic hepatitis B.Methods MEDLINE, SCI, Current Content Connect, The Cochrane Library, and Chinese Biomedical Database were searched from the beginning to September 2005, and the references of eligible studies were manually screened. R.andomized controlled trials comparing lamivudine with non-antiviral interventions ( placebo, no treatment and standard care ) in patients with chronic hepatitis B were eligible for inclusion. Two investigators independently assessed the quality and extracted the data. Heterogeneity was examined by Chi-square test. Fixed and random effect meta-analysis were used to pool the data. Subgroup analyses were used in treatment course. Results Eleven R.CTs were included ( n = 1 237 ). All reported the effect of lamivudine (100 mg/d) , and one of them included lamivudine (25 mg/d). The treatment duration of 52 weeks and less than 26 weeks were reported in eight and three RCTs, respectively. Six RCTs adequately applied randomization, while other five RCTs were not reported in detail. Four RCTs adequately enforced allocation concealment, five RCTs enforced blinding bitterly. The others were not reported in detail. It was found by meta-analysis that, compared with the control, lamivudine (100 mg/d, 52 W) could significantly clear HBeAg [42.6% vs. 13% , RR 3.20, 95% CI (2.33, 4. 38)] and clearHBVDNA [71.78% vs. 20, 36%, RR3.42, 95%CI (2.80,4.19)], normalize ALT [65% vs. 34.9%, RR1.91, 95%CI (1.64,2.21)], achieve HBeAgseroconversion [16.1% vs. 7.29% , RR2.12, 95%CI (1.24,3.80) ] and histology response [57. 9% vs. 26.2%, RR 2. 17, 95% CI ( 1.67,2.81 ) ] ; Lanfivudine (100 mg/ d, 12 W) could effectively clear HBV DNA [ 50.7% vs 3.92% , RR 8.68, 95% CI (1.72,43.74 ) ] , but was not effective in loss of HBeAg, HBeAg seroconversion and normalization of ALT, Lamivudine (25 mg/d) could effectively clear HBV DNA [97.7% vs. 22.2% , RR 4.41, 95% CI (2.86,6.79) ] and improve histology response [59.3% vs. 30% , RR1.98, 95% CI (1.31,2.99 ) ], but was not effective in HBeAg seroconversion. Conclusions Lamivudine (100 mg/ d) is effective in clearing HBV DNA and HBeAg, normalizing ALT and achieving HBeAg seroconversion.

    Release date:2016-08-25 03:34 Export PDF Favorites Scan
  • Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation

    ObjectiveTo investigate the efficacy of lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV reinfection after liver transplantation. MethodsThe clinical data of 76 cases of HBV-related liver disease after liver transplantation using lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV re-infection were retrospectively analyzed, and the HBV re-infection risk factors were analyzed. ResultsSeventy-six patients' HBsAg became negative after liver transplantation, HBV re-infect in 9 cases.The re-infection rate was 9.2% (7/76) and 11.8% (9/76), respectively, in 1-year and 2-year after liver transplantation. ConclusionsLamivudine combined with low-dose hepatitis B immune globulin after liver transplantation can be effective preventing re-infection with HBV.HBeAg positive and HBV-DNA positive before liver transplantation is risk factors of HBV re-infection.

    Release date: Export PDF Favorites Scan
  • Interferon-α Combined with Lamivudine for Children with Hepatitis B: A Meta-Analysis

    Objective To systematically review the effectiveness and safety interferon-α (IFN-α) combined with lamivudine vs. IFN-α alone in treating children with Hepatitis B. Methods Such databases as The Cochrane Library, PubMed, EMbase, Web of Science, CBM, CNKI, VIP and WanFang Data were electronically searched for randomized controlled trials (RCTs) on IFN-α combined with lamivudine in treating children with hepatitis B. Two reviewers screened literature, extracted data, and assessed the methodological quality of the included studies. Then, meta-analysis was performed using RevMan 5.0 software. Results 8 RCTs were included, with comparable baseline. The results of meta-analysis showed that, compared to the IFN-α alone group, the combined therapy group had higher negative rates of serum HBV-DNA and HBeAg. There was no significant difference in the positive rate of anti-Hbe and the incidence of adverse reaction between the two groups. Conclusion Current evidence shows that IFN-α combined with lamivudine was more effective than IFN-α alone in treating children’s hepatitis B.

    Release date: Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content